Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 12, 2013, Pages 1407-1409

  Keung, Benison ^a   Robeson, Kimberly R ^a   DiCapua, Daniel B ^a   Rosen, Jennifer B ^a   O'Connor, Kevin C ^a   Goldstein, Jonathan M ^a   Nowak, Richard J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYCLOSPORIN; MUSCLE SPECIFIC KINASE AUTOANTIBODY POSITIVE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PYRIDOSTIGMINE; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; BLOOD CELL COUNT; CHILL; CLINICAL ARTICLE; DYSARTHRIA; FEMALE; FLUSHING; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; IMMUNOASSAY; IMMUNOTHERAPY; INFUSION RELATED REACTION; LETTER; LIVER FUNCTION TEST; MALE; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; PLASMAPHERESIS; PRIORITY JOURNAL; PRURITUS; REFRACTORY PERIOD; RETROSPECTIVE STUDY; RIGOR; SIDE EFFECT;

EID: 84888058235     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-303664     Document Type: Letter

References (9)

1. Wolfe GI, Oh SJ. Clinical phenotype of muscle-specific tyrosine kinase-antibody-positive myasthenia gravis. Ann NY Acad Sci 2008;1132:71-5.
2. Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol 2008;201-202:90-4.
3. Díaz-Manera J, Martínez-Hernández E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012;78:189-93.
4. Nowak RJ, Dicapua DB, Zebardast N, et al. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011;4:259-66.
5. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011;82:671-3.
6. Collongues N, Casez O, Lacour A, et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve 2012;46:687-91.
7. Lebrun C, Bourg V, Tieulie N, et al. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur J Neurol 2009;16:246-50.
8. Barohn RJ. Standards of measurements in myasthenia gravis. Ann NY Acad Sci 2003;998:432-9.
9. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40.